Document Detail

Diagnosis and management of scleroderma peripheral vascular disease.
MedLine Citation:
PMID:  18329535     Owner:  NLM     Status:  MEDLINE    
The manifestations of peripheral vascular disease in patients who have systemic sclerosis (SSc) range from episodic Raynaud's phenomenon to irreversible tissue injury with ulceration and gangrene. Structural and functional changes may occur in the microvessels, digital arteries, and sometimes more proximal vessels. This article discusses the assessment of patients who have Raynaud's phenomenon in whom an underlying scleroderma-spectrum disorder is suspected and patients who have SSc with critical digital ischemia/ulceration. Different imaging techniques, including capillaroscopy and angiography, complement the history and examination, and developments in vascular imaging should facilitate future studies of pathogenesis and treatment response. New vasoactive treatments are currently being researched and older treatments revisited; therefore new approaches to therapy will likely be developed over the next 5 to 10 years.
Ariane Herrick
Related Documents :
2119515 - Role of aggressive factors in the pathogenesis of peptic ulcer disease.
21185615 - Glucometabolic state in chinese patients undergoing elective coronary angiography.
24001675 - Short-term functional outcome of ischemic stroke in the elderly: a comparative study of...
12435345 - Serum concentrations of elastin-derived peptides in patients with specific manifestatio...
979785 - Bilateral renal calculi in patients receiving methyldopa.
9236315 - Contrast sonography for inconclusive findings on routine sonography.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Rheumatic diseases clinics of North America     Volume:  34     ISSN:  0889-857X     ISO Abbreviation:  Rheum. Dis. Clin. North Am.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-03-10     Completed Date:  2008-05-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8708093     Medline TA:  Rheum Dis Clin North Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  89-114; vii     Citation Subset:  IM    
Rheumatic Diseases Centre, University of Manchester, Salford Royal NHS Foundation Trust, Salford M6 8HD, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antioxidants / therapeutic use
Microscopic Angioscopy
Prostaglandins, Synthetic / therapeutic use
Raynaud Disease / complications,  diagnosis,  drug therapy*
Scleroderma, Systemic* / diagnosis,  drug therapy
Vasodilator Agents / therapeutic use*
Reg. No./Substance:
0/Antioxidants; 0/Prostaglandins, Synthetic; 0/Vasodilator Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Regulation of vascular reactivity in scleroderma: new insights into Raynaud's phenomenon.
Next Document:  Fibrosis in systemic sclerosis.